IronBridge Capital Management LP reduced its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 31.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 268,421 shares of the medical instruments supplier’s stock after selling 124,608 shares during the period. West Pharmaceutical Services accounts for 1.3% of IronBridge Capital Management LP’s portfolio, making the stock its 16th largest position. IronBridge Capital Management LP owned approximately 0.37% of West Pharmaceutical Services worth $21,906,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of WST. JPMorgan Chase & Co. increased its position in West Pharmaceutical Services by 10.1% in the first quarter. JPMorgan Chase & Co. now owns 2,031,582 shares of the medical instruments supplier’s stock worth $165,798,000 after buying an additional 186,692 shares during the period. Quantbot Technologies LP bought a new position in West Pharmaceutical Services during the first quarter worth approximately $712,000. Private Advisor Group LLC increased its position in West Pharmaceutical Services by 3.2% in the first quarter. Private Advisor Group LLC now owns 2,899 shares of the medical instruments supplier’s stock worth $232,000 after buying an additional 91 shares during the period. Pacer Advisors Inc. increased its position in West Pharmaceutical Services by 19.1% in the first quarter. Pacer Advisors Inc. now owns 9,655 shares of the medical instruments supplier’s stock worth $788,000 after buying an additional 1,549 shares during the period. Finally, Mason Street Advisors LLC increased its position in West Pharmaceutical Services by 1.3% in the first quarter. Mason Street Advisors LLC now owns 34,609 shares of the medical instruments supplier’s stock worth $2,824,000 after buying an additional 453 shares during the period. 91.59% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Shares of West Pharmaceutical Services, Inc. (NYSE WST) opened at 95.97 on Monday. West Pharmaceutical Services, Inc. has a one year low of $70.17 and a one year high of $99.91. The stock has a 50 day moving average of $96.29 and a 200 day moving average of $86.55. The stock has a market cap of $7.06 billion, a P/E ratio of 39.72 and a beta of 1.11.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, April 27th. The medical instruments supplier reported $0.81 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.26. West Pharmaceutical Services had a return on equity of 14.89% and a net margin of 11.88%. The company had revenue of $387.70 million during the quarter, compared to analyst estimates of $380.42 million. During the same period last year, the company posted $0.53 earnings per share. The firm’s quarterly revenue was up 7.1% compared to the same quarter last year. Equities analysts expect that West Pharmaceutical Services, Inc. will post $2.73 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 2nd. Stockholders of record on Wednesday, July 19th will be paid a $0.13 dividend. The ex-dividend date is Monday, July 17th. This represents a $0.52 dividend on an annualized basis and a dividend yield of 0.54%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 21.40%.

COPYRIGHT VIOLATION WARNING: “IronBridge Capital Management LP Cuts Stake in West Pharmaceutical Services, Inc. (WST)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/06/19/ironbridge-capital-management-lp-sells-124608-shares-of-west-pharmaceutical-services-inc-wst-updated-updated-updated.html.

Several brokerages have issued reports on WST. Zacks Investment Research raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a research report on Saturday. BidaskClub downgraded shares of West Pharmaceutical Services from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $90.00 price objective on shares of West Pharmaceutical Services in a research report on Thursday, June 8th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $90.18.

In related news, CFO William J. Federici sold 54,996 shares of West Pharmaceutical Services stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $95.45, for a total value of $5,249,368.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel Malone sold 4,124 shares of West Pharmaceutical Services stock in a transaction dated Tuesday, May 2nd. The stock was sold at an average price of $93.31, for a total value of $384,810.44. The disclosure for this sale can be found here. Company insiders own 1.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Receive News & Stock Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related stocks with our FREE daily email newsletter.